View Older Stories View More Recent Stories
-
Biohaven Pharma (BHVN) Misses Q1 EPS by 4c
-
Biohaven Pharma (BHVN) files mixed shelf
-
Canaccord Starts Biohaven Pharma (BHVN) at Buy
-
Biohaven Pharma (BHVN) PT Raised to $17 at Citi
-
Biohaven Pharma (BHVN) PT Raised to $28 at Jefferies
-
Raymond James on Biohaven Pharma (BHVN): 'results continue to highlight an opportunity for opakalim'
-
Biohaven Pharma (BHVN) PT Lowered to $10 at H.C. Wainwright
-
Leerink Partners Reiterates Outperform Rating on Biohaven Pharma (BHVN), lowers EPS estimates
-
Biohaven Pharma (BHVN) PT Raised to $23 at RBC Capital
-
Piper Sandler: 'Biohaven Pharma (BHVN) Gearing Up for a Catalyst-Rich 2026'
-
Biohaven Pharma (BHVN) Tops Q4 EPS by 28c
-
Piper Sandler on Biohaven Pharma (BHVN): 'We like the risk/reward at current levels'
-
Goldman Sachs Starts Biohaven Pharma (BHVN) at Buy
-
RBC Capital Upgrades Biohaven Pharma (BHVN) to Outperform
-
Bairdon Biohaven (BHVN): 'e think case studies from today's presentation answers the major question lingering for BHV-1400'
-
Biohaven reports early patient data from protein degrader programs
-
Stifel Reiterates Xenon Pharmaceuticals (XENE) at Buy following Biohaven's failure
-
H.C. Wainwright Reiterates Neutral Rating on Biohaven Pharmaceutical Holding (BHVN)
-
Biohaven Pharma (BHVN) call put ratio 1 call to 1 put as share price lower before the bell
-
Biohaven shares cancer drug trial results at European oncology meeting
-
H.C. Wainwright Downgrades Biohaven Pharmaceutical Holding (BHVN) to Neutral
-
UBS Downgrades Biohaven Pharmaceutical Holding (BHVN) to Neutral
-
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $26 at Morgan Stanley
-
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $14 at Citi
-
William Blair Reiterates Market Perform Rating on Biohaven Pharmaceutical Holding (BHVN)
-
Biohaven Pharma (BHVN) Tops Q3 EPS by 24c
-
Piper Sandler Slashes Biohaven Pharmaceutical (BHVN) Stock PT as 'FDA Says No to Troriluzole'
-
Bernstein SocGen Group Downgrades Biohaven Pharmaceutical Holding (BHVN) to Market Perform
-
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $15 at Leerink Partners
-
BofA Securities Downgrades Biohaven Pharmaceutical Holding (BHVN) to Neutral
-
Raymond James Comments on Biohaven (BHVN) Post Management Call
-
William Blair Downgrades Biohaven Pharmaceutical Holding (BHVN) to Market Perform
-
JPMorgan on Biohaven Pharmaceutical (BHVN): 'expect the stock to be under some pressure'
-
William Blair on Biohaven (BHVN): 'Expect Weakness'
-
Morgan Stanley on Biohaven (BHVN): 'The next catalyst for the stock is Opakalim (BHV-7000; Kv7 activator) Ph2/3 data in major depressive disorder (MDD)'
-
Raymond James on Biohaven Pharmaceutical Holding (BHVN): 'Meaningful Value Remains', 'Sticking with it'
-
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $42 at Baird
-
FDA rejects Biohaven drug application for rare brain disorder
-
Truist: 'QURE Update Minimal Read-Through To PTCT & WVE, In Our View'
-
Raymond James on Biohaven (BHVN) Amid News Shock: 'QURE Sympathy Move Seems Misplaced'
-
Biohaven Pharma (BHVN) Weakness May Be Tied to uniQure (QURE) Setback in Huntington's Disease
-
Citi Starts Biohaven Pharmaceutical Holding (BHVN) at Buy
-
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $26 at UBS
-
RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'
-
Why public perception matters so much for biotech valuations
-
Increasing unusual put option volume: FIVN OPEN BHVN XLB XLI ONDS LQDA ROST
-
Biohaven receives FDA update on troriluzole drug application
-
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $60 at BTIG
-
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $30 at H.C. Wainwright
-
Increasing unusual put option volume: OPEN BHVN ATYR TAP SBET XLP ACN LITE MSOS DOCN SHW

